OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - BAVARIAN NORDIC | Real-time Boerse Frankfurt Warrants 01:24:26 03/06/2024 pm IST | ||
| 8.07 EUR | -0.25% |
|
| 1 month | +107.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BAVARIAN NORDIC A/S
Latest news about BAVARIAN NORDIC A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 8.07 | -0.25% |
| 31/24/31 | 8.09 | +12.99% |
| 30/24/30 | 7.16 | +4.99% |
| 29/24/29 | 6.82 | -6.06% |
| 28/24/28 | 7.26 | -0.41% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 01:24 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BAVARIAN NORDIC A/S |
| Issuer | 
Société Générale
|
| WKN | SW9P3T |
| ISIN | DE000SW9P3T8 |
| Date issued | 29/04/2024 |
| Strike | 124.4 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 3.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.25 € |
|---|---|
| Lowest since issue | 3.64 € |
| Spread | 0.04 € |
| Spread % | 0.49% |
Company Profile
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%).
Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).
Sector
-
Consensus: Bavarian Nordic A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
184.8
DKK
Average target price
262
DKK
Spread / Average Target
+41.74%
- Stock Market
- Certificates
- Certificat
